Chinese Company Refuses GMP Inspection and Gets an Import Alert from the FDA

Recommendation
26-29 August 2025
Copenhagen, Denmark
including 8 Interactive Workshops
The US FDA has placed the Chinese company Beijing Shunxin Meihua Bio-technical Co on an import alert. Consequently, the company cannot deliver any product to the US market. According to the information portal Regulatory Focus, the import alert was published on 22 July 2014. Last year, the FDA referred to its competence in a Guideline and emphasised the fact that any refusal or obstruction to an inspection would have immediate consequences. You can read more on the topic in our GMP News "Denying, Delaying, And Refusing: How to Fail a FDA Inspection". Already in the past, a Chinese company got a Warning Letter after it had thrown three FDA inspectors out of the facility.
Related GMP News
02.07.2025EFPIA Report on Current Inspections
18.06.2025FDA Warning Letter with Supplier Qualification Observations
11.06.2025Root Cause Investigations criticised at EU Company
21.05.2025More FDA Warning Letters citing Quality Oversight
21.05.2025New Version of GMP Auditors Handbook available
21.05.2025FDA: more unannounced Inspections also outside the US